FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Masahide Kubo

Research Profile

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Biological Markers

Anatomy

Physiology

Up-Regulation

Phenomena

Fluorescent Antibody Technique, Indirect

Co-author Network

Publications

TOP 3
Manabu Tomita; Norihito Yazawa; Makoto Sugaya; Kunihiko Tamaki; Zenshiro Tamaki; Yoshihide Asano; Ryuichi Ashida; Hironobu Ihn; Takafumi Kadono; Tomohiko Kawashima; Masahide Kubo; Hanako Ohmatsu; Shinichi Sato
Serum levels of soluble CD21 in patients with systemic sclerosis.
Tomohiko Kawashima; Yayoi Tada; Yoshihide Asano; Norihito Yazawa; Manabu Tomita; Zenshiro Tamaki; Masahide Kubo; Hironobu Ihn; Makoto Sugaya; Takafumi Kadono; Kunihiko Tamaki; Shinichi Sato
Serum TARC/CCL17 levels are increased in dermatomyositis associated with interstitial lung disease.
Ryuichi Ashida; Hironobu Ihn; Yoshihiro Mimura; Masatoshi Jinnin; Yoshihide Asano; Masahide Kubo; Kunihiko Tamaki
Clinical and laboratory features of Japanese patients with scleroderma and telangiectasia.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Masahide Kubo (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Manabu Tomita; Norihito Yazawa; Makoto Sugaya; Kunihiko Tamaki; Zenshiro Tamaki; Yoshihide Asano; Ryuichi Ashida; Hironobu Ihn; Takafumi Kadono; Tomohiko Kawashima; Masahide Kubo; Hanako Ohmatsu; Shinichi Sato
Serum levels of soluble CD21 in patients with systemic sclerosis.
Rheumatology international 2012;32(2):317-21.
2010: Tomohiko Kawashima; Yayoi Tada; Yoshihide Asano; Norihito Yazawa; Manabu Tomita; Zenshiro Tamaki; Masahide Kubo; Hironobu Ihn; Makoto Sugaya; Takafumi Kadono; Kunihiko Tamaki; Shinichi Sato
Serum TARC/CCL17 levels are increased in dermatomyositis associated with interstitial lung disease.
Journal of dermatological science 2010;60(1):52-4.
2009: Ryuichi Ashida; Hironobu Ihn; Yoshihiro Mimura; Masatoshi Jinnin; Yoshihide Asano; Masahide Kubo; Kunihiko Tamaki
Clinical and laboratory features of Japanese patients with scleroderma and telangiectasia.
Clinical and experimental dermatology 2009;34(7):781-3.
2009: K Shimane; Yuta Kochi; Ryo Yamada; Y Okada; Akinori Suzuki; Akihiko Miyatake; Masahide Kubo; Yusuke Nakamura; Kazuhiko Yamamoto
A single nucleotide polymorphism in the IRF5 promoter region is associated with susceptibility to rheumatoid arthritis in the Japanese population.
Annals of the rheumatic diseases 2009;68(3):377-83.
2008: Zenshiro Tamaki; Masahide Kubo; Norihito Yazawa; Yoshihiro Mimura; Ryuichi Ashida; Manabu Tomita; Yayoi Tada; Tomohiko Kawashima; Kunihiko Tamaki
Serum levels of soluble CD26 in patients with scleroderma.
Journal of dermatological science 2008;52(1):67-9.
2007: Ryuichi Ashida; Hironobu Ihn; Yoshihiro Mimura; Masatoshi Jinnin; Yoshihide Asano; Masahide Kubo; Kunihiko Tamaki
Clinical features of scleroderma patients with contracture of phalanges.
Clinical rheumatology 2007;26(8):1275-7.
2007: Yoshihiro Mimura; Norihito Yazawa; Zenshirou Tamaki; Ryuichi Ashida; Masatoshi Jinnin; Yoshihide Asano; Yayoi Tada; Masahide Kubo; Hironobu Ihn; Kunihiko Tamaki
Anti-p53 antibodies in patients with dermatomyositis/polymyositis.
Clinical rheumatology 2007;26(8):1328-31.
2006: Yoshihide Asano; Hironobu Ihn; Masahide Kubo; Masatoshi Jinnin; Yoshihiro Mimura; Ryuichi Ashida; Kunihiko Tamaki
Clinical significance of serum matrix metalloproteinase-13 levels in patients with localized scleroderma.
Clinical and experimental rheumatology 2006;24(4):394-9.
2006: Masahide Kubo; Hironobu Ihn; Kenichi Yamane; Kunihiko Tamaki
The expression levels and the differential expression of transforming growth factor-beta receptors in dermatofibroma and dermatofibrosarcoma protuberans.
The British journal of dermatology 2006;154(5):919-25.
2006: Yoshihide Asano; Hironobu Ihn; Masahide Kubo; Masatoshi Jinnin; Yoshihiro Mimura; Ryuichi Ashida; Kunihiko Tamaki
Clinical significance of serum levels of matrix metalloproteinase-13 in patients with systemic sclerosis.
Rheumatology (Oxford, England) 2006;45(3):303-7.
2004: Yoshihide Asano; Hironobu Ihn; Kenichi Yamane; Masahide Kubo; Kunihiko Tamaki
Increased expression levels of integrin alphavbeta5 on scleroderma fibroblasts.
The American journal of pathology 2004;164(4):1275-92.
2004: Yoshihide Asano; Hironobu Ihn; Kenichi Yamane; Masahide Kubo; Kunihiko Tamaki
Impaired Smad7-Smurf-mediated negative regulation of TGF-beta signaling in scleroderma fibroblasts.
The Journal of clinical investigation 2004;113(2):253-64.
2003: Yoshihide Asano; Hironobu Ihn; Kenichi Yamane; Masahide Kubo; Kunihiko Tamaki
The prevalence and clinical significance of anti-U1 RNA antibodies in patients with systemic sclerosis.
The Journal of investigative dermatology 2003;120(2):204-10.
2002: Masahide Kubo; Hironobu Ihn; Kenichi Yamane; Kunihiko Tamaki
Upregulated expression of transforming growth factor-beta receptors in dermal fibroblasts of skin sections from patients with systemic sclerosis.
The Journal of rheumatology 2002;29(12):2558-64.
2002: Hironobu Ihn; Yoshihide Asano; Masahide Kubo; Kenichi Yamane; Masatoshi Jinnin; Norihito Yazawa; Manabu Fujimoto; Kunihiko Tamaki
Clinical significance of serum surfactant protein D (SP-D) in patients with polymyositis/dermatomyositis: correlation with interstitial lung disease.
Rheumatology (Oxford, England) 2002;41(11):1268-72.
2002: Kenichi Yamane; Hironobu Ihn; Masahide Kubo; Kunihiko Tamaki
Increased transcriptional activities of transforming growth factor beta receptors in scleroderma fibroblasts.
Arthritis and rheumatism 2002;46(9):2421-8.
2002: Masahide Kubo; Hironobu Ihn; Yoshihide Asano; Kenichi Yamane; Norihito Yazawa; Kunihiko Tamaki
Prevalence of 52-kd and 60-kd Ro/SS-A autoantibodies in Japanese patients with polymyositis/dermatomyositis.
Journal of the American Academy of Dermatology 2002;47(1):148-51.
2002: Kanako Kikuchi; Masahide Kubo; Toshihiko Hoashi; Kunihiko Tamaki
Decreased MMP-9 activity in the serum of patients with diffuse cutaneous systemic sclerosis.
Clinical and experimental dermatology 2002;27(4):301-5.
2002: Masahide Kubo; Hironobu Ihn; M Kuwana; Yoshihide Asano; T Tamaki; Kenichi Yamane; Kunihiko Tamaki
Anti-U5 snRNP antibody as a possible serological marker for scleroderma-polymyositis overlap.
Rheumatology (Oxford, England) 2002;41(5):531-4.
2002: Hironobu Ihn; Kenichi Yamane; Yoshihide Asano; Masahide Kubo; Kunihiko Tamaki
IL-4 up-regulates the expression of tissue inhibitor of metalloproteinase-2 in dermal fibroblasts via the p38 mitogen-activated protein kinase dependent pathway.
Journal of immunology (Baltimore, Md. : 1950) 2002;168(4):1895-902.
2001: Masahide Kubo; Hironobu Ihn; M Kuwana; Kenichi Yamane; Norihito Yazawa; Kunihiko Tamaki
Prevalence in myositis of antibodies recognizing anti-U3 RNA probably in a novel complex with 22/25 kD protein and not fibrillarin.
Clinical and experimental immunology 2001;126(2):339-44.
2001: Kenichi Yamane; Hironobu Ihn; Masahide Kubo; M Kuwana; Yoshihide Asano; Norihito Yazawa; Kunihiko Tamaki
Anti-U1RNP antibodies in patients with localized scieroderma.
Archives of dermatological research 2001;293(9):455-9.
2001: Kenichi Yamane; Hironobu Ihn; Masahide Kubo; M Kuwana; Yoshihide Asano; Norihito Yazawa; Kunihiko Tamaki
Antibodies to Th/To ribonucleoprotein in patients with localized scleroderma.
Rheumatology (Oxford, England) 2001;40(6):683-6.
2001: Yoshihide Asano; Hironobu Ihn; Kenichi Yamane; Norihito Yazawa; Masahide Kubo; Manabu Fujimoto; Kunihiko Tamaki
Clinical significance of surfactant protein D as a serum marker for evaluating pulmonary fibrosis in patients with systemic sclerosis.
Arthritis and rheumatism 2001;44(6):1363-9.
2001: Masahide Kubo; Hironobu Ihn; Kenichi Yamane; Kunihiko Tamaki
Up-regulated expression of transforming growth factor beta receptors in dermal fibroblasts in skin sections from patients with localized scleroderma.
Arthritis and rheumatism 2001;44(3):731-4.
2001: Hironobu Ihn; Kenichi Yamane; Masahide Kubo; Kunihiko Tamaki
Blockade of endogenous transforming growth factor beta signaling prevents up-regulated collagen synthesis in scleroderma fibroblasts: association with increased expression of transforming growth factor beta receptors.
Arthritis and rheumatism 2001;44(2):474-80.
2000: Kenichi Yamane; Hironobu Ihn; Yoshihide Asano; Norihito Yazawa; Masahide Kubo; Kanako Kikuchi; Y Soma; Kunihiko Tamaki
Clinical and laboratory features of scleroderma patients with pulmonary hypertension.
Rheumatology (Oxford, England) 2000;39(11):1269-71.
2000: Masahide Kubo; Hironobu Ihn; Kenichi Yamane; Norihito Yazawa; Kanako Kikuchi; Y Soma; Kunihiko Tamaki
Increased serum levels of soluble vascular cell adhesion molecule-1 and soluble E-selectin in patients with polymyositis/dermatomyositis.
The British journal of dermatology 2000;143(2):392-8.
2000: Masahide Kubo; Hironobu Ihn; Kenichi Yamane; Kanako Kikuchi; Norihito Yazawa; Y Soma; Kunihiko Tamaki
Serum KL-6 in adult patients with polymyositis and dermatomyositis.
Rheumatology (Oxford, England) 2000;39(6):632-6.
2000: Kenichi Yamane; Hironobu Ihn; Masahide Kubo; Norihito Yazawa; Kanako Kikuchi; Y Soma; Kunihiko Tamaki
Serum levels of KL-6 as a useful marker for evaluating pulmonary fibrosis in patients with systemic sclerosis.
The Journal of rheumatology 2000;27(4):930-4.
2000: Hironobu Ihn; Norihito Yazawa; Masahide Kubo; Kenichi Yamane; Shinichi Sato; Manabu Fujimoto; Kanako Kikuchi; Y Soma; Kunihiko Tamaki
Circulating levels of soluble CD30 are increased in patients with localized scleroderma and correlated with serological and clinical features of the disease.
The Journal of rheumatology 2000;27(3):698-702.
2000: Norihito Yazawa; Kanako Kikuchi; Hironobu Ihn; Manabu Fujimoto; Masahide Kubo; T Tamaki; Kunihiko Tamaki
Serum levels of tissue inhibitor of metalloproteinases 2 in patients with systemic sclerosis.
Journal of the American Academy of Dermatology 2000;42(1 Pt 1):70-5.
2000: Kenichi Yamane; Hironobu Ihn; Masahide Kubo; Norihito Yazawa; Kanako Kikuchi; Y Soma; Kunihiko Tamaki
Increased serum levels of soluble vascular cell adhesion molecule 1 and E-selectin in patients with localized scleroderma.
Journal of the American Academy of Dermatology 2000;42(1 Pt 1):64-9.
2000: Hironobu Ihn; Shinichi Sato; M Fujimoto; A Igarashi; Norihito Yazawa; Masahide Kubo; K Kikuchi; K Takehara; Kunihiko Tamaki
Characterization of autoantibodies to endothelial cells in systemic sclerosis (SSc): association with pulmonary fibrosis.
Clinical and experimental immunology 2000;119(1):203-9.
1999: Hironobu Ihn; Kenichi Yamane; Norihito Yazawa; Masahide Kubo; M Fujimoto; Shinichi Sato; K Kikuchi; Kunihiko Tamaki
Distribution and antigen specificity of anti-U1RNP antibodies in patients with systemic sclerosis.
Clinical and experimental immunology 1999;117(2):383-7.
1999: Masahide Kubo; Hironobu Ihn; A Matsukawa; Kanako Kikuchi; Kunihiko Tamaki
Dermatomyositis with elevated serum hyaluronate.
Clinical and experimental dermatology 1999;24(4):275-8.
1999: Masahide Kubo; Hironobu Ihn; Norihito Yazawa; Shinichi Sato; Kanako Kikuchi; Kunihiko Tamaki
Prevalence and antigen specificity of anti-histone antibodies in patients with polymyositis/dermatomyositis.
The Journal of investigative dermatology 1999;112(5):711-5.
1998: Kanako Kikuchi; Masahide Kubo; T Kadono; Norihito Yazawa; Hironobu Ihn; Kunihiko Tamaki
Serum concentrations of vascular endothelial growth factor in collagen diseases.
The British journal of dermatology 1998;139(6):1049-51.
1998: Masahide Kubo; Kanako Kikuchi; Norihito Yazawa; Manabu Fujimoto; T Tamaki; Kunihiko Tamaki
Increased serum concentration of hyaluronate in dermatomyositis patients.
Archives of dermatological research 1998;290(10):579-81.
1998: Masahide Kubo; Kanako Kikuchi; K Nashiro; Takashi Kakinuma; N Hayashi; H Nanko; Kunihiko Tamaki
Expression of fibrogenic cytokines in desmoplastic malignant melanoma.
The British journal of dermatology 1998;139(2):192-7.
1998: Masahide Kubo; Kanako Kikuchi; Manabu Fujimoto; Kunihiko Tamaki
Serum concentrations of carboxyterminal propeptide of type 1 procollogen and tissue inhibitor of metalloproteinase 1 in patients with dermatomyositis.
Archives of dermatological research 1998;290(5):253-7.
1998: Norihito Yazawa; Manabu Fujimoto; Kanako Kikuchi; Masahide Kubo; Hironobu Ihn; Shinichi Sato; T Tamaki; Kunihiko Tamaki
High seroprevalence of Helicobacter pylori infection in patients with systemic sclerosis: association with esophageal involvement.
The Journal of rheumatology 1998;25(4):650-3.
1997: Manabu Fujimoto; Kanako Kikuchi; T Tamaki; Norihito Yazawa; Masahide Kubo; Hironobu Ihn; Shinichi Sato; Y Soma; Kunihiko Tamaki
Distribution of anti-p80-coilin autoantibody in collagen diseases and various skin diseases.
The British journal of dermatology 1997;137(6):916-20.
1996: T Kadono; K Kikuchi; Masahide Kubo; Manabu Fujimoto; Kunihiko Tamaki
Serum concentrations of basic fibroblast growth factor in collagen diseases.
Journal of the American Academy of Dermatology 1996;35(3 Pt 1):392-7.
1996: Masahide Kubo; Shinichi Sato; H Kitahara; T Tsuchida; Kunihiko Tamaki
Vesicle formation in dermatomyositis associated with gynecologic malignancies.
Journal of the American Academy of Dermatology 1996;34(2 Pt 2):391-4.
1995: K Kikuchi; Masahide Kubo; Shinichi Sato; Manabu Fujimoto; Kunihiko Tamaki
Serum tissue inhibitor of metalloproteinases in patients with systemic sclerosis.
Journal of the American Academy of Dermatology 1995;33(6):973-8.